Dry eye is a general term for a variety of pathological conditions characterized by damage to the ocular surface due to tear film abnormalities and is one of the most common ophthalmic diseases. Some studies have reported that about 15% of elderly people have symptoms of dry eye. With the increasing popularity of computer applications, more and more young people are suffering from dry eye. According to a survey, the percentage of people who suffer from dry eye among frequent computer users is as high as 31.2%. Cyclosporine as an immunosuppressant used locally in the eye can inhibit T-cell activation, reduce lymphocyte infiltration, reduce the inflammatory response of the ocular surface and lacrimal gland, and inhibit conjunctival cupped cell apoptosis, so it has a good therapeutic effect on dry eye. Foreign scholars such as Bohnke and Kaswan used 0.05%, 0.1%, 0.2%, 0.4% cyclosporine ophthalmic emulsion to treat 1260 patients with dry eyes and achieved good efficacy. Therefore, the U.S. FDA first approved Allergan’s 0.05% cyclosporine ophthalmic emulsion on December 26, 2002, under the trade name RestasisTM.